about
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemiaSafety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasPentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.Comparison of automated platelet counts and potential effect on transfusion decisions in cancer patients.Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.Monoclonal antibody therapy of APL.Diagnosis and treatment of acute promyelocytic leukemia.Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesUsing the hemoglobin content of reticulocytes (RET-He) to evaluate anemia in patients with cancer.Evaluation of new automated hematopoietic progenitor cell analysis in the clinical management of peripheral blood stem cell collections.Comparison of manual hematocrit determinations versus automated methods for hematopoietic progenitor cell apheresis products.Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.Morphologic identification of atypical chronic lymphocytic leukemia by digital microscopy.Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial.Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapyPilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemiaAcute myeloid leukemia with t(5;18)(q35;q21)Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphomaA phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemiaPegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?Grading follicular lymphomas in fine-needle aspiration biopsies: the role of ThinPrep slides and flow cytometryAcanthocytesA pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal diseaseAcute myeloid leukemiaAntibody-drug conjugates in acute myeloid leukemiaAcute myeloid leukemiaPhase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemiaSingle-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell MyelomaAzacitidine and the beginnings of therapeutic epigenetic modulation
P50
Q29617590-778E5295-C108-4554-8D3A-EE00C4B0C7C3Q29622949-6019D567-3BF0-46B1-A245-DF674FF41517Q33347187-4E79A7C8-2733-4D51-89DF-2656F7CBF605Q33378530-FF49F6EC-6E8F-4CD7-9459-F394BF472DFBQ33410920-8C1E5DDB-3C21-45A9-A9D0-FB34D8B276BAQ34022415-4BC2E93F-3100-4A7A-B339-6A48BFE27EA8Q34369388-B8435C2C-E95E-45CE-BD37-641A74E6C72AQ36704978-96D3767B-9A4F-43B6-A45D-2965EB63674CQ36913223-82E93DEE-604E-4C50-9B1C-88345FEAE59BQ37104775-5FE07AF9-4252-4A34-A9AB-4017247A445FQ37129166-5F4BE2F4-6B71-478E-9F0E-BB98AB1BF9F5Q37158660-9C19A252-A2EC-42BD-BF8B-D05F168C66C9Q37165707-B560544E-84F0-4551-8236-68FC56F2A544Q37659113-6BD6E54D-B2DC-4577-92CF-FE0997DF696FQ37731754-D39A2772-D61A-479F-ADD5-FCF3A99952FBQ38393438-7FDBEF87-9628-4993-8CF6-788DD450506BQ39215504-2829965F-BAFF-45A9-AEB4-021FFEF8594AQ40715769-F4C1EDE6-11EE-4A6D-9378-9ED44128E3B6Q40994724-422578AE-844D-40BE-BF1F-4EEC2215AD91Q43961349-EED5A30C-97BC-43BE-BE43-5D0FE9C7A797Q46853686-15E2E5D5-52E2-4261-BC7C-864A82A2B843Q47798161-3E04EF2A-0C42-4604-8040-3A883E945081Q51909196-FF225A00-F85D-4D16-BB07-CF2469E0DD67Q61637095-B4467A49-13CE-44DC-9F2B-39A7AF1CFCF8Q70944899-DDD37A4A-BDBF-41E6-B9B9-83896AE3C134Q74025321-C49D4D2A-D19D-4F72-B6E8-65C42CB07C26Q74360817-CED35CD5-5325-4E3E-BFCD-AC264E267E2CQ74696438-0039A0AC-8D23-4E59-BB9E-66F5B83710DEQ80147886-EBA96578-79F6-4B97-A15C-13A3CB759310Q80177814-F3B7F254-846E-4EA2-89AF-6400E8D9F60CQ80219033-A4AF081E-4877-4575-B0AC-D28A5A0AF8B8Q80651051-D56F05A7-2185-4387-8E80-EC35C66EE24EQ83255922-2C07627C-8062-43D6-A903-D0C73F674711Q83305766-C3EC28DF-9B28-4E4F-8CEF-2EEAE2A6304FQ83584384-E68435E3-B3F2-4132-A449-46532CEF85F6Q87656028-5DAA842C-072B-4D1B-B610-FE71234DFC0DQ87870251-900EB1A5-8D89-4536-9556-F51D875ED681Q94704305-8AF6DC9F-B634-4A31-B617-D8624EA6FE9B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter G Maslak
@ast
Peter G Maslak
@en
Peter G Maslak
@es
Peter G Maslak
@nl
type
label
Peter G Maslak
@ast
Peter G Maslak
@en
Peter G Maslak
@es
Peter G Maslak
@nl
prefLabel
Peter G Maslak
@ast
Peter G Maslak
@en
Peter G Maslak
@es
Peter G Maslak
@nl
P106
P31
P496
0000-0003-1949-5819